First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC

Molecular Testing and Treatment Selection in NSCLC: Guidelines for Physicians

Importance of Pre-Treatment Molecular Testing

• Critical priority: Avoid hastily initiating treatment before obtaining molecular testing results
• Standard treatment for NSCLC without targetable mutations is combination chemotherapy and immunotherapy
• Starting treatment prematurely may expose patients to unnecessary toxicities and complicate subsequent therapeutic options

EGFR-Positive NSCLC Treatment Considerations

• EGFR-positive patients can receive single oral targeted therapy as primary treatment, avoiding chemotherapy and immunotherapy
• First-line EGFR agents like osimertinib offer:
• Improved survival benefits

• Excellent central nervous system penetration

• Minimal comparative toxicity
• Warning: Starting immunotherapy prior to osimertinib in EGFR-positive patients may:
• Increase risk of severe immune-related adverse events

• Preclude osimertinib use until immunotherapy is completely cleared

Guideline Comparison: ASCO vs NCCN

ASCO Guidelines

• EGFR Exon 19 deletion/Exon 21 L858R substitution:
• Primary recommendation: Osimertinib monotherapy

• Alternative consideration: Osimertinib with chemotherapy
• Atypical EGFR mutations:
• Weaker recommendation for afatinib or osimertinib
• EGFR Exon 20 insertion:
• Chemotherapy and amivantamab, or standard non–driver alteration treatments

NCCN Guidelines

• Generally broader recommendations, including all FDA-approved options
• EGFR Exon 19 deletion/Exon 21 L858R:
• Multiple options: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib with chemotherapy, or amivantamab plus lazertinib
• Atypical EGFR mutations:
• Any monotherapy EGFR tyrosine kinase inhibitors without preference between afatinib or osimertinib
• EGFR Exon 20 insertion:
• Similar to ASCO: amivantamab plus chemotherapy as first-line recommendation